- Home
- GATX vs TGTX Comparison
GATX vs TGTX Comparison
Compare GATX & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GATX
- TGTX
- Stock Information
- Founded
- GATX 1898
- TGTX 1993
- Country
- GATX United States
- TGTX United States
- Employees
- GATX N/A
- TGTX N/A
- Industry
- GATX Transportation Services
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- GATX Consumer Discretionary
- TGTX Health Care
- Exchange
- GATX Nasdaq
- TGTX Nasdaq
- Market Cap
- GATX 5.9B
- TGTX 5.1B
- IPO Year
- GATX N/A
- TGTX 1995
- Fundamental
- Price
- GATX N/A
- TGTX $35.05
- Analyst Decision
- GATX Strong Buy
- TGTX Strong Buy
- Analyst Count
- GATX 3
- TGTX 6
- Target Price
- GATX $182.00
- TGTX $47.50
- AVG Volume (30 Days)
- GATX 192.1K
- TGTX 1.8M
- Earning Date
- GATX 10-21-2025
- TGTX 11-03-2025
- Dividend Yield
- GATX 1.40%
- TGTX N/A
- EPS Growth
- GATX 34.45
- TGTX N/A
- EPS
- GATX 8.74
- TGTX 0.36
- Revenue
- GATX $1,671,000,000.00
- TGTX $454,069,000.00
- Revenue This Year
- GATX $11.26
- TGTX $82.22
- Revenue Next Year
- GATX $5.50
- TGTX $47.76
- P/E Ratio
- GATX $19.90
- TGTX $94.64
- Revenue Growth
- GATX 11.74
- TGTX 30.96
- 52 Week Low
- GATX $130.95
- TGTX $22.61
- 52 Week High
- GATX $178.26
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- GATX 59.54
- TGTX 58.24
- Support Level
- GATX $168.64
- TGTX $33.10
- Resistance Level
- GATX $175.32
- TGTX $37.45
- Average True Range (ATR)
- GATX 3.16
- TGTX 1.24
- MACD
- GATX -0.68
- TGTX -0.09
- Stochastic Oscillator
- GATX 72.99
- TGTX 53.49
About GATX GATX Corporation
GATX Corp is a provider of railcar leasing and maintenance services. GATX operates in business segments including rail North America, rail international, Engine Leasing, and others. The rail business offers railcar leasing and maintenance, as well as asset-related, financial, and management services. The company owns and leases fleets in North America, Europe, and Asia, which consist of tank and freight railcars. Industries served include refining and petroleum, chemicals and plastics, railroads and other transportation, mining, and food and agriculture.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.